May 2025 – MiP Pharma, a portfolio company of capiton, announces the successful sale of its production site in Homburg/Saar to the Famar Group, a globally operating pharmaceutical CDMO. The Famar Group will integrate the facility into its global production network and further develop it. For MiP Pharma, this step is a key part of its growth strategy, which will focus on the distribution of its own pharmaceutical products in the future.
Over the past two years, MiP Pharma, supported by capiton, has made significant investments in the expansion, consolidation, and modernization of the site. These measures included the installation of new packaging lines, the expansion of laboratory capacities, and extensive technical upgrades. These improvements have transformed the facility into a highly attractive site for international partners.
Alexander Zamora, Partner at capiton, commented: “We are proud to have actively supported the expansion of the Homburg site. The sale not only ensures the sustainable development of the site but also lays the foundation for MiP Pharma’s future growth. This is a pivotal step in the company’s strategic direction.”
Dr. Friedrich Sernetz, CEO of MiP Pharma, added: “Thanks to the investments, the Homburg facility has become an attractive site for global pharmaceutical specialists. The sale enables us to focus on our core competency – the distribution of our pharmaceutical products – and to accelerate our growth.”
With this transaction, capiton AG continues its successful strategy of actively supporting companies in their transformation and growth while creating sustainable value.
About MiP Pharma
The MiP Pharma Group markets prescription generics, primarily antibiotics, as well as over-the-counter medicines and medical devices. The main markets are Germany, Poland, and other Eastern European countries. The sales focus is on the hospital business and addressing specialized medical groups. With over 200 employees and around 400 marketing authorizations, MiP Pharma generated sales of approximately €50 million in the last financial year. Since November 2020, MiP Pharma has been part of the portfolio of the Berlin-based private equity firm capiton AG.
About capiton
capiton is an independent, owner-managed private equity firm with a total fund volume of €1.6 billion. The current investment portfolio of capiton AG includes 18 medium-sized companies. As an equity partner, capiton supports management buy-outs and growth financing for established medium-sized businesses.